Successful treatment of disseminated nasal T-cell lymphoma using high-dose chemotherapy and autologus peripheral blood stem cell transplantation: a case report.
It is reported that the prognosis of relapse nasal lymphoma is invariably fatal, and high-dose chemotherapy using autologous peripheral blood stem cell transplantation (auto-PBSCT) has been established as an effective treatment for patients with relapsing aggressive non-Hodgkin's lymphoma. We experienced a case with T-cell lymphoma in the nasal cavity that relapsed after the initial treatment consisting of chemotherapy and radiation therapy. We treated with high-dose chemotherapy and auto-PBSCT to the patient. The patient has been disease free without therapy for 30 months following auto-PBSCT. Our experience suggests that high-dose chemotherapy using auto-PBSCT may be one of effective treatment option for relapsed nasal T-cell lymphoma when conventional chemotherapy fails.
Kouzaki
Hideaki
H
Department of Otolaryngology, Shiga University of Medical Science, Tsukinowa, Seta, Otsu 520-2192, Japan. hkohzaki@belle.shiga-med.ac.jp
Kitanishi
Tsuyoshi
T
Kitano
Hiroya
H
Suzuki
Mikio
M
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D016399:Lymphoma, T-Cell / Q000628:therapy*; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D009296:Nasal Cavity; D009669:Nose Neoplasms / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D016879:Salvage Therapy; D014057:Tomography, X-Ray Computed; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D008942:Mitoxantrone; D002945:Cisplatin; D011241:Prednisone